The discovery of RNA interference (RNAi) in 1998 earned Andrew Fire and Craig Mello the Nobel Prize in Physiology or Medicine in 2006, recognizing a fundamental biological mechanism that has since transformed therapeutic development . Small interfering RNA (siRNA) represents one of the most promising classes of RNAi therapeutics, offering the ability to selectively silence disease-causing genes through post-transcriptional gene silencing. The Small Interfering RNA Market is experiencing remarkable growth as this technology matures from experimental research to commercially viable medicine. The global market size was worth over USD 18.33 billion in 2025 and is poised to witness a CAGR of more than 13.9%, crossing USD 67.36 billion revenue by 2035 .

The Science of Gene Silencing

The Small Interfering RNA Market is built on a sophisticated understanding of how double-stranded RNA molecules can trigger sequence-specific degradation of messenger RNA, effectively preventing the expression of pathogenic proteins . This mechanism offers a highly specific treatment approach with broad applicability across rare genetic, metabolic, cardiovascular, hepatic, ophthalmic, neurological, and oncology indications . By preventing the expression of disease-driving proteins rather than merely inhibiting their function, siRNA therapeutics offer the potential for long-lasting effects with infrequent dosing. The market is segmented by application, with cancer treatment leading in market share due to the high prevalence of cancer and demand for innovative therapeutic approaches. Neurological disorders are gaining notable traction as an emergent field, reflecting promising opportunities for siRNA technologies to address complex diseases such as Alzheimer's and Parkinson's .

Key Drivers: Personalized Medicine and Regulatory Success

Several powerful factors are fueling the growth of the Small Interfering RNA Market. A primary driver is the rising popularity of personalized medicine, as siRNA has emerged as a promising possibility for precision therapy in cancer and other diseases due to its highly specific nature and ability to be easily generated for multiple target genes . A second critical factor is the growing geriatric population, which is more susceptible to age-related diseases such as Alzheimer's, Huntington's, and Parkinson's that may benefit from siRNA treatment . The increasing number of regulatory approvals is strengthening clinical confidence in RNAi therapeutics and expanding the modality across multiple disease areas, with recent approvals for ATTR amyloidosis with cardiomyopathy, hemophilia A or B, and familial chylomicronemia syndrome . Furthermore, advances in RNA chemistry and targeted delivery technologies are improving the stability, potency, and clinical utility of siRNA therapeutics.

Market Segmentation and Regional Landscape

The Small Interfering RNA Market is segmented by type, synthetic route, delivery system, mechanism of action, and application. By delivery system, lipid nanoparticles dominate the landscape, providing efficient delivery mechanisms for RNA therapeutics, while viral vectors are emerging as a powerful and innovative delivery system . By synthetic route, chemical synthesis has established itself as the largest segment due to its widespread application and reliability in high-yield production, while biotechnology is rapidly gaining traction . Regionally, North America leads the market, supported by a strong biotechnology ecosystem and advanced research capabilities . The Asia Pacific market is projected to secure the second largest share by 2035, driven by biotechnology advancements in countries like India .

Future Outlook and Strategic Opportunities

The future of the Small Interfering RNA Market is exceptionally promising, with a projected CAGR of over 13% indicating substantial growth potential. Key opportunities lie in the development of targeted RNAi therapeutics for rare diseases and the expansion of RNAi delivery systems in clinical settings . Companies such as Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Ionis Pharmaceuticals are actively shaping the market through strategic collaborations, licensing agreements, and pipeline expansion . The recent FDA approval of Arrowhead's Redemplo (plozasiran) for familial chylomicronemia syndrome marks a significant milestone, demonstrating the commercial viability of siRNA therapeutics . By 2035, the Small Interfering RNA Market is expected to be robust, playing a pivotal role in the era of precision medicine.